Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ziprasidone hydrochloride, quantity: 65.16 mg (equivalent: ziprasidone, qty 60 mg) - capsule, hard - excipient ingredients: gelatin; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; pregelatinised maize starch - for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy;,as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ziprasidone hydrochloride, quantity: 21.72 mg (equivalent: ziprasidone, qty 20 mg) - capsule, hard - excipient ingredients: gelatin; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; indigo carmine; colloidal anhydrous silica; titanium dioxide - for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy;,as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 87.2 mg - capsule, hard - excipient ingredients: purified water; sodium starch glycollate type b; gelatin; ammonium chloride; lactose monohydrate; indigo carmine; sodium lauryl sulfate; titanium dioxide; macrogol 6000; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 65.4 mg - capsule, hard - excipient ingredients: sodium starch glycollate type b; macrogol 6000; ammonium chloride; indigo carmine; sodium lauryl sulfate; purified water; sucrose; gelatin; lactose monohydrate; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 43.6 mg - capsule, hard - excipient ingredients: indigo carmine; purified water; gelatin; macrogol 6000; sodium starch glycollate type b; ammonium chloride; lactose monohydrate; titanium dioxide; sodium lauryl sulfate; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 21.8 mg - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; sodium starch glycollate type b; purified water; sucrose; titanium dioxide; ammonium chloride; sodium lauryl sulfate; indigo carmine; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - bupropion hydrochloride extended-release tablets, (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies (14.1)]. bupropion hydrochloride extended-release tablets, (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets, (xl) in the pr

United States - English - NLM (National Library of Medicine)

dr reddys laboratories inc - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies (14.1)]. bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets (xl) in the prevention of seasonal major depressive episodes was established in 3 plac

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoclopramide hydrochloride monohydrate, quantity: 5.25 mg (equivalent: metoclopramide hydrochloride, qty 5 mg); paracetamol, quantity: 500 mg - capsule, hard - excipient ingredients: magnesium stearate; colloidal anhydrous silica; purified talc; sodium starch glycollate; titanium dioxide; brilliant blue fcf; sunset yellow fcf; quinoline yellow; potable water; gelatin; sodium lauryl sulfate; brilliant scarlet 4r; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for symptomatic relief of headache, nausea and vomiting associated with migraine.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - paracetamol; guaifenesin; phenylephrine hydrochloride - oral capsule - 500mg ; 100mg ; 6.1mg